Blog

Combinations Required to Further Advance Adoptive T-Cell Therapy – OncLive


OncLive

Combinations Required to Further Advance Adoptive TCell Therapy
OncLive
A variety of adoptive Tcell therapy strategies have shown promise in clinical trials with recent FDA approvals granted to chimeric antigen receptor (CAR)-modified Tcell therapies, representing the potential for future combination strategies

2017-11-09 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.